Humanitas Research Hospital – Department of Neurology

Humanitas Research Hospital and University is a highly specialized teaching and research hospital recognized for the quality of healthcare services. More than 300 researchers from 16 countries, spanning over 4 continents, work here Hospital in close collaboration with the 650 house physicians.
The Department of Neurology at Humanitas employs a team of skilled neurologists dedicated to the diagnosis and treatment of diseases of the central and peripheral nervous system. Main clinical and research interests of the department are: degenerative diseases of the nervous system, peripheral neuropathies, and cerebrovascular disease. We are particularly renowned in the field of Parkinson’s disease, dystonia, parkinsonian syndromes, immune-mediated neuropathies and amyotrophic lateral sclerosis.
The Department of Neurology aims to ensure the patient a high quality standard of diagnosis and treatment of all neurological diseases, while at the same time fostering innovative clinical and translational research.

Humanitas Research Hospital – Department of Neurology
Foundation year	1996
Director	Alberto Albanese, MD
Principal investigator	Alberto Albanese, MD

Contact information
Address	Via Alessandro Manzoni 56 20089 Rozzano (Milano) Italy
Contact	Alberto Albanese
Phone	+39 02 8224 6418
Email	alberto.albanese@humanitas.it
Website	Visit the website

Publications

• Elia AE, Lalli S, Monsurro MR, Sagnelli A, Taiello AC, Reggiori B, La Bella, V, Tedeschi, G., Albanese, A. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur J Neurol 2016 Jan;23(1):45-52.
• Riva N, Clarelli F, Domi T, Cerri F, Gallia F, Trimarco A, Brambilla P, Lunetta C, Lazzerini A, Lauria G, Taveggia C, Iannaccone S, Nobile-Orazio E, Comi G, D’Antonio M, Martinelli-Boneschi F, Quattrini A. Unraveling gene expression profiles in peripheral motor nerve from amyotrophic lateral sclerosis patients: insights into pathogenesis. Sci Rep. 2016 Dec 16;6:39297.
• Marino M, Papa S, Crippa V, Nardo G, Peviani M, Cheroni C, Trolese MC, Lauranzano E, Bonetto V, Poletti A, DeBiasi S, Ferraiuolo L, Shaw PJ, Bendotti C. Differences in protein quality control correlate with phenotype variability in 2 mouse models of familial amyotrophic lateral sclerosis. Neurobiol Aging. 2015 Jan;36(1):492-504.
• Nardo G, Pozzi S, Pignataro M, Lauranzano E, Spano G, Garbelli S, Mantovani S, Marinou K, Papetti L, Monteforte M, Torri V, Paris L, Bazzoni G, Lunetta C, Corbo M, Mora G, Bendotti C, Bonetto V. Amyotrophic lateral sclerosis multiprotein biomarkers in peripheral blood mononuclear cells. PLoS One. 2011;6(10):e25545.
• Terenghi F, Allaria S, Nobile-Orazio E. Circulating levels of cytokines and their modulation by intravenous immunoglobulin in multifocal motor neuropathy. J Peripher Nerv Syst. 2006 Mar;11(1):67-71.

For other publications, see: https://www.humanitas.net/units/neurology/

Restricted information

Serving population
Serving population	Lombardy, Italy

Patient resources
Population based register	No
Clinic based register	Yes
Geographically matched controls	No

Banks

Type	ALS Patients	Controls	Other
Serum Bank (in progress)

Research activities
Clinical management research	Yes
Neuro epidemiology	No
Neuro physiology	No
Neuro imaging	No
Neuro psychology	No
Neuro pathology	Yes
Genomics	No
Transcriptomics	No
Metabolomics	No

Clinical Trials - Industry sponsored

There are no clinical trials for this centre

Clinical Trials - Investigator initiated

Name	Type	Patients
Safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS)	Phase III; Randomised; Placebo controlled; Double blind. [Sponsor]	440
Translating molecular mechanisms into ALS risk and patient’s well-being (TRANS-ALS)	Observational study. [Partner]	300
A randomized, double-blind pilot study vs. placebo for the evaluation of efficacy and tolerability of tauroursodeoxycholic acid administered by oral route as add on treatment in patients affected by amyotrophic lateral sclerosis	Phase II; Randomised; Placebo controlled; Double blind [Sponsor]	34